Market News

Cresco Labs a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary located at 3900 N 9 th Ave. in Pensacola, FL. Sunnyside Pensacola is the Company’s second store in the Panhandle region. With today’s opening, Cresco Labs operates 12 Florida stores and 44 nationwide. This press release features ...

Cresco Labs (CSE:CL) (OTCQX:CRLBF) ("Cresco Labs" or "the Company"), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary located at 3900 N 9 th Ave. in Pensacola, FL. Sunnyside Pensacola is the Company's second store in the Panhandle region. With today's opening, Cresco Labs operates 12 Florida stores and 44 nationwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005308/en/

Cresco Labs' new Pensacola dispensary is its second in Florida's Panhandle and 44th nationwide. (Photo: Business Wire)

"This is our fourth Florida new store opening since the closing of the Bluma Wellness acquisition, and we're on target to double our store count in the state by the anniversary date," said Charlie Bachtell, CEO and Co-founder of Cresco Labs. "We're going deeper and expanding accessibility to our branded products in the two biggest medical markets, Florida and Pennsylvania. We're already the top seller of branded cannabis in Pennsylvania, and we're excited to expand access to those same amazing products to patients throughout Florida."

Sunnyside Pensacola is centrally located in the city near Cordova Mall, across the bridge from Pensacola Beach and the suburb of Gulf Breeze, and a few blocks away from Interstate 110—offering broad accessibility to daily commuters and residents.

The store will serve patients with a medical card issued by the state of Florida. Patients can place orders online through the Sunnyside.shop website or utilize next-day delivery. Orders can also be placed both in-store or via phone at 877-395-1009. Regular store hours are Monday through Saturday, 10AM to 8PM, and Sunday, 10AM to 5PM.

About Cresco Labs Inc.

Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods ("CPG") approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy's Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs' national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry's largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com .

Forward Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,' ‘will,' ‘should,' ‘could,' ‘would,' ‘expects,' ‘plans,' ‘anticipates,' ‘believes,' ‘estimates,' ‘projects,' ‘predicts,' ‘potential' or ‘continue' or the negative of those forms or other comparable terms. The Company's forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under "Risk Factors" in the Company's Annual Information Form for the year ended December 31, 2020 filed on March 26, 2021, and other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company's forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs' shares, nor as to the Company's financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company's forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.

Media:
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com

Investor Relations:
investors@crescolabs.com

For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com

News Provided by Business Wire via QuoteMedia

business person cutting a cost sign

Cannabis Weekly Round-Up: HEXO Plans Cost Savings to Improve Cash Generation

This week, a Canadian licensed cannabis producer shared its plan to cut on costs as it aims to reach a better cash flow line over the next two fiscal years.

Meanwhile, a planned acquisition from a US-based multi-state operator (MSO) has now been dismantled.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading... Show less

Trulieve Announces Resale Registration Statement Filings

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced that it publicly filed a resale registration on Form S-1 (the "Registration Statement") with the United States Securities and Exchange Commission ("SEC") on January 21, 2022 to register for resale Subordinate Voting Shares of the Company issued as consideration for previously announced 2021 acquisitions.

Keep reading... Show less

Harvest and Trulieve Celebrate One Year Anniversary of Recreational Cannabis Sales in Arizona

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced plans to celebrate the one year anniversary of recreational cannabis sales in Arizona through a series of in-store activations, product specials and celebrations. All Trulieve-affiliated Harvest locations will have doorbuster deals on January 21 - 22 and the company will host a rooftop event at The Clarendon Hotel on Saturday, January 22 .

Keep reading... Show less
Little Green Pharma logo

LGP Signs Exclusive Distribution Agreement With Pharmaserve Hellas

Greece added to rapidly expanding EU distribution portfolio. LGP now has distribution agreements in 5 EU territories including France, Denmark, Germany, Poland and Greece.

Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to announce its entry into an exclusive agreement with PharmaServe Hellas SMSACI (“PharmaServe”) for the distribution of LGP-branded oil medicines and cannabis flower in Greece (“Agreement”).

Keep reading... Show less
Numinus Wellness Inc. Reports Q1 2022 Results

Numinus Wellness Inc. Reports Q1 2022 Results

  • Ended quarter with strong cash position of $53.9 million
  • Revenues grew 245% year-over-year to $0.8 million for the quarter
  • Generated gross profit of $50,965 during the quarter, representing a 6.5% gross margin
  • Well-positioned to offer psychedelic-assisted psychotherapy services through Canada's newly expanded Special Access Program
  • Clinical trial application made to Health Canada to begin Phase 1 study for proprietary psilocybe extract
  • MAPS-sponsored MDMA-Assisted Therapy for PTSD study to begin shortly; approvals received from Health Canada and the Institutional Review Board

All financial results are reported in Canadian dollars unless otherwise stated.

Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its fiscal first quarter results for the three months ended November 30, 2021 .

Keep reading... Show less
AYURCANN HOLDINGS CORP. UPDATE FOR 2022

AYURCANN HOLDINGS CORP. UPDATE FOR 2022

Ayurcann Holdings Corp. ( CSE: AYUR OTCQB: CDCLF FSE: 3ZQ0 ) (the " Company "), a leading Canadian cannabis extraction company specializing in the processing and co-manufacturing of pharma grade cannabis and hemp to produce various derivative cannabis 2.0 products in the medical and recreational market, is pleased to provide an update to its exponential growth throughout Canada.

Ayurcann Market segments

Keep reading... Show less

Latest Press Releases

Related News

×